L-asparaginase in the treatment of neoplastic diseases in children.
D000293:Adolescent; D000970:Antineoplastic Agents; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D001856:Bone Marrow Examination; D001859:Bone Neoplasms / Q000188:drug therapy; D002051:Burkitt Lymphoma / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007223:Infant; D007680:Kidney Neoplasms / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008099:Liver / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D009447:Neuroblastoma / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012512:Sarcoma, Ewing / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D009396:Wilms Tumor / Q000188:drug therapy
D000970:Antineoplastic Agents; D001215:Asparaginase; D011241:Prednisone; D006854:Hydrocortisone